.jpeg)
2026-07-13 07:34:24
The U.S. FDA approved Gilead’s Trodelvy (sacituzumab govitecan) on June 24, 2026, for first-line treatment of advanced triple-negative breast cancer (TNBC), based on Phase III ASCENT-03 and ASCENT-04 data.
2026-07-10 06:43:53
An in-depth analysis of Cabozantinib's multi-kinase inhibition mechanism and its established role in treating renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer globally.
2026-07-10 06:37:28
This article provides a comprehensive overview of infusion-related reactions (IRRs) associated with Amivantamab. It covers preventive premedication, step-up dosing strategies, and protocols for managing adverse events in clinical settings.
2026-06-30 03:12:23
A roundup of recent cancer case studies and pharmaceutical innovations, highlighting long-term survivors of advanced malignancies and the debut of China's first global-first bispecific ADC drug.
2026-06-30 03:05:30
Lusutrombopag is a small molecule oral thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a planned invasive procedure.
2026-06-29 06:44:46
Pretomanid is a novel nitroimidazole anti-tuberculosis agent and a core component of the BPaL regimen for extensively drug-resistant (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB). This article covers its mechanism of action, efficacy profile, indications and safe use guidelines.
2026-06-26 04:06:33
Fezolinetant is an NK3 receptor antagonist primarily used to treat menopausal hot flashes. This article provides an in-depth analysis of its relationship with depression, including current research evidence, indirect mood benefits from hot flash improvement, and clinical prescribing recommendations to help patients correctly understand the drug's scope of use.
2026-06-26 03:49:45
Fezolinetant is a novel NK3 receptor antagonist used to treat moderate to severe vasomotor symptoms (hot flashes) associated with menopause. This article provides a detailed overview of the incidence, clinical presentation, and management strategies for its common side effects, helping patients use the medication safely and effectively manage discomfort.
2026-06-26 03:21:39
Belumosudil is an oral selective ROCK2 inhibitor indicated for the treatment of chronic graft-versus-host disease (cGVHD) in patients who have failed at least two prior systemic therapies. This article provides a comprehensive overview of its efficacy data, real-world patient experiences, side effect management, and steroid-sparing effects to help patients fully understand this treatment option.
2026-06-26 03:06:36
Brivaracetam is a high-affinity SV2A ligand drug for partial-onset seizures. This article explains its mechanism, long-term use principles, discontinuation risks, evaluation criteria, tapering regimens, and special population considerations to guide safe medication discontinuation.
2026-06-25 06:42:02
Learn the principles of discontinuing mirogabalin for neuropathic pain. This guide covers physical dependence, stepwise tapering, withdrawal symptom management, and special population adjustments.
2026-06-25 06:34:59
Pretomanid is a novel anti-TB agent that kills dormant mycobacteria, enabling shorter, all-oral regimens for XDR-TB. This article covers its mechanism, BPaL trial results, safety, and clinical role.
